A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) (NCT04970901)

🧪 Interventions in This Study

• Loncastuximab Tesirine (DRUG)
• Polatuzumab Vedotin (DRUG)
• Glofitamab (DRUG)
• Mosunetuzumab (DRUG)
• Obinutuzumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (40 Sites)

Showing the first 25 of 40 sites.

• University of California San Francisco - Fresno Center for Medical Education and Research — Clovis, California
• Scripps Health - Prebys Cancer Center — San Diego, California
• Sylvester Comprehensive Cancer Center — Miami, Florida
• Miami Cancer Institute — Miami, Florida
• Memorial Cancer Institute - Memorial Hospital West — Pembroke Pines, Florida
• Winship Cancer Institute of Emory University — Atlanta, Georgia
• The Blood and Marrow Transplant Group of Georgia — Atlanta, Georgia
• Mission Cancer + Blood - Mission Cancer Foundation — Des Moines, Iowa
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• University of Minnesota — Minneapolis, Minnesota
• Columbia University Irving Medical Center — New York, New York
• Cleveland Clinic Main Campus — Cleveland, Ohio
• Oregon Health and Science University — Portland, Oregon
• Penn Medicine - Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
• Allegheny Health Network - West Penn Hospital — Pittsburgh, Pennsylvania
• Brown University Health - Rhode Island Hospital — Providence, Rhode Island
• Hollings Cancer Center — Charleston, South Carolina
• Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR) — Nashville, Tennessee
• Baylor University Medical Center — Dallas, Texas
• Huntsman Cancer Institute — Salt Lake City, Utah
• Emily Couric Clinical Cancer Center — Charlottesville, Virginia
• NEXT Virginia (Virginia Cancer Specialists) — Fairfax, Virginia
• Froedtert & Medical College of Wisconsin — Milwaukee, Wisconsin
• Universitair Ziekenhuis Gent — Ghent,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in B-Cell Non-Hodgkin Lymphoma

• Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma — Chicago, Illinois
• A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma — Birmingham, Alabama
• Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma — Seattle, Washington
• DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas — Miami, Florida
• Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment — Winston-Salem, North Carolina

Explore by condition: All B-Cell Non-Hodgkin Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.